What are the side effects of ibrutinib?
Ibrutinib is a kinase inhibitor used to treat patients with mantle cell lymphoma (MCL) and patients who have been treated with at least one other chemotherapy drug . For the treatment of patients with chronic lymphocytic leukemia(CLL) and small lymphocytic lymphoma(SLL). It is used to treat Waldenström's macroglobulinemia(WM), to treat patients with marginal zone lymphoma(MZL), and to treat patients with chronic graft-versus-host disease(cGVHD)It can begin some time after transplantation and continue long after treatment with one or more drugs has failed.

For patients with MCL, common effects of ibrutinib include increased serum creatinine, thrombocytopenia(57%), and diarrhea(51%), bleeding(48%), neutropenia(47%), decreased hemoglobin(41%)< /span>, fatigue(41%), musculoskeletal pain(37%), peripheral edema(35%) , URIinfection(34%), nausea(31%)(21%), cough(19%), fever(18%), stomatitis(17%), thrombocytopenia, 3 grade or 4 grade(17%), UTIviral infection< /span>(14%), pneumonia(14%), skin infection(14%), weakness(14%), muscle cramps
For cGvHD patients, common side effects of ibrutinib include fatigue(57%) and bruising(40%) span>, diarrhea(36%), thrombocytopenia(33%), stomatitis(29%), muscle cramps(29%), nausea(26%), bleeding(26%), decreased hemoglobin(24%), pneumonia(21%), upper respiratory tract infection(19%)< span>, fever(17%), headache(17%), fall(17%), Musculoskeletal pain(14%), pneumonia, grade 3 or grade 4
For patients withCLL, common effects of ibrutinib include thrombocytopenia(71%), diarrhea(63%), and bruising(54%), neutropenia(54%), URTinfection(48%), hemoglobin decrease(44%)
xa0
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)